The abstract is read at the publisher; the summary is JClub's.
Higher RHBDL2 expression is associated with chemoresistance and poor prognosis in patients with triple-negative breast cancer (TNBC), and RHBDL2 knockdown suppresses stemness and resistance in TNBC cells.
- Why it matters: Chemoresistance limits TNBC treatment, yet the molecular drivers of resistance and cancer stemness are not well defined.
- What they did: The study linked RHBDL2 to TNBC chemoresistance by knocking down RHBDL2 to inhibit CD44+/CD24− breast cancer stem cells, supported by RNA sequencing and pathway analysis of EGFR/PI3K/AKT/mTOR/c-MYC.
- The result: RHBDL2 activated EGFR/PI3K/AKT/mTOR/c-MYC by binding EGFR, and RHBDL2 knockdown reduced EGFR on the TNBC cell membrane and inhibited tumor growth in xenograft models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.